Syntimmune Taps Ex-Boehringer, Pfizer Exec as New CEO

Xconomy New York — 

New York-based Syntimmune has named David de Graaf, a former Boehringer-Ingelheim and Pfizer executive, its president and CEO. The startup has also appointed Burt Adelman, the former research chief of Dyax and previously Biogen, to its board of directors. Adelman was named a senior adviser to Syntimmune as well.